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ABSTRACT
Objective Transient receptor potential canonical 5
(TRPC5) is functionally expressed on a range of cells
including ﬁbroblast-like synoviocytes, which play an
important role in arthritis. A role for TRPC5 in
inﬂammation has not been previously shown in vivo.
We investigated the contribution of TRPC5 in
arthritis.
Methods Male wild-type and TRPC5 knockout (KO)
mice were used in a complete Freund’s adjuvant
(CFA)-induced unilateral arthritis model, assessed over
14 days. Arthritis was determined by measurement of
knee joint diameter, hindlimb weightbearing
asymmetry and pain behaviour. Separate studies
involved chronic pharmacological antagonism of
TRPC5 channels. Synovium from human postmortem
control and inﬂammatory arthritis samples were
investigated for TRPC5 gene expression.
Results At baseline, no differences were observed.
CFA-induced arthritis resulted in increased synovitis in
TRPC5 KO mice assessed by histology. Additionally,
TRPC5 KO mice demonstrated reduced ispilateral
weightbearing and nociceptive thresholds (thermal
and mechanical) following CFA-induced arthritis. This
was associated with increased mRNA expression of
inﬂammatory mediators in the ipsilateral synovium
and increased concentration of cytokines in synovial
lavage ﬂuid. Chronic treatment with ML204, a
TRPC5 antagonist, augmented weightbearing
asymmetry, secondary hyperalgesia and cytokine
concentrations in the synovial lavage ﬂuid. Synovia
from human inﬂammatory arthritis demonstrated a
reduction in TRPC5 mRNA expression.
Conclusions Genetic deletion or pharmacological
blockade of TRPC5 results in an enhancement in
joint inﬂammation and hyperalgesia. Our results
suggest that activation of TRPC5 may be associated
with an endogenous anti-inﬂammatory/analgesic
pathway in inﬂammatory joint conditions.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic, systemic
autoimmune disease characterised by inﬂammation
of diarthrodial joints, joint tenderness and swel-
ling.1 RA affects 1% of the worldwide population
and initiates with inﬂammation of the synovium in
peripheral joints, which progresses to destruction
of articular cartilage, leading to signiﬁcant joint
degeneration, pain and loss of function.1 2
Transient receptor potential (TRP) channels are
non-selective cation channels, which are involved
in divergent somatosensory functions, including
pain.3 Several members of TRP channels, in par-
ticular, TRP vanilloid 1 and TRP ankyrin 1 , play a
detrimental role in inﬂammatory pain conditions,
including arthritis,4 in addition to being involved in
vascular regulation.5 We have shown that pharma-
cological blockade or genetic deletion of these
channels is associated with an improved outcome
of adjuvant-induced arthritis in mice.4
TRP canonical 5 (TRPC5) is a member of the
canonical family of TRP channels that assemble to
form non-selective cation channels as homo-
tetramers or hetero-tetramers.3 TRPC5 more com-
monly associates with other members of TRPC
channels, notably, TRPC1 and TRPC4.6 TRPC5 is
expressed in the central nervous system7 and per-
ipherally in sensory nerves.8 9 While there is
limited evidence of a functional role in arthritis in
vivo, TRPC5, together with TRPC1, are expressed
in CD55+ ﬁbroblast-like synoviocytes (FLS).10
Stimulation of TRPC5 by the endogenous agonist,
thioredoxin, results in a suppression of matrix
metalloproteinases (MMPs) secretion in both
humans and animal FLS, highlighting a conserved
effect. Furthermore, blockade of TRPC5 by anti-
body or siRNA treatment potentiated MMP-2
secretion from FLS of patients with RA.10
Pharmacological tools for TRPC5 channels are
limited;6 however, a TRPC4/5 antagonist, ML204,
was characterised as selective antagonist with
19-fold selectivity over TRPC6.11 ML204 exhibited
stability in vitro, with a half-life of 2 h and was also
functionally effective in vivo.12 Global TRPC5
knockout (KO) mice show normal survival, fertility
and growth compared with wild-type (WT) control
mice;7 however, the functional signiﬁcance of
TRPC5 in inﬂammatory joint disease is unclear. We
hypothesised that global deletion or pharmaco-
logical antagonism of TRPC5 would exacerbate
joint disease associated with increased inﬂammation
and pain.
MATERIALS AND METHODS
The full methods are provided in the online
supplementary material.
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Mice
Male, age-matched 129S1/SvImJ TRPC5 WT and TRPC5 KO
bred from established breeding pairs7 were used at 8–12 weeks
of age. All experiments were conducted under United Kingdom
Home Ofﬁce Animals (Scientiﬁc Procedures) Act 1986 and
approved by the King’s College London Animal Care and Ethics
Committees.
Induction of arthritis
The complete Freund’s adjuvant (CFA)-induced unilateral arth-
ritis model was investigated over 14 days, as characterised previ-
ously.4 Behavioural measurements of hyperalgesia were obtained
at baseline and stated timepoints.
Histology and immunoﬂuorescence staining
Histological and immunoﬂuorescence staining was performed as
previously described.4 13
Human tissue sample collection
All live and postmortem (PM) donations were obtained at
Sherwood Forest Hospitals NHS Foundation Trust,
Sutton-in-Ashﬁeld, UK. Synovium from the knee was collected
during arthroplastic surgery or at the time of PM examination
and stored at −80°C until RNA extraction. Three groups,
non-arthritic cases, RA and osteoarthritic (OA) cases, were
selected to be age and, if possible, sex matched, as previously
described.14 Patient details including inﬂammatory scores are
described in online supplementary table S1.
Statistical analysis
Results are expressed as mean±SEM and analysed by two-way
analysis of variance and Bonferroni post hoc test using Graph
Pad Prism V.5.0 (San Diego, California, USA) unless stated. For
non-parametric data (human mRNA expression), results were
analysed using Kruskal–Wallis test followed by post hoc Dunn’s
comparison. Signiﬁcance was accepted as p<0.05.
RESULTS
Deletion of TRPC5 exacerbates chronic CFA-induced arthritis
We examined the mRNA expression of TRPC5 in the mouse
synovium 14 days following CFA-induced arthritis and observed
a signiﬁcant reduction in the expression of TRPC5 in the ipsilat-
eral synovium compared with the contralateral synovium in WT
mice (p<0.01; ﬁgure 1A). This reduction in TRPC5 expression
was not associated with regulation of associated members of
TRPC channels as no signiﬁcant difference was observed in the
expression of TRPC1, TRPC3 or TRPC6 (see online
supplementary table S4) and we did not detect TRPC4 expres-
sion. Double-immunoﬂuorescence labelling illustrated the
expression of TRPC5 in the intimal and subintimal lining of the
mouse synovium (ﬁgure 1B), with co-localisation with CD55
observed mostly in the intimal lining, as previously described.10
The functional contribution of TRPC5 in vivo was investigated
by assessing mobility and movement-related pain over a period
of 14 days, following CFA-induced arthritis. We found a signiﬁ-
cant reduction in the ipsilateral hindlimb weightbearing of WT
mice (approximately 10%) compared with baseline by day 7,
which was modestly ameliorated by day 14 (ﬁgure 1C). Genetic
deletion of TRPC5 resulted in an enhanced discomfort and exa-
cerbated weightbearing asymmetry on day 14 (approximately
10%), compared with WT mice.
TRPC5 regulates hyperalgesia in CFA-induced arthritis
Hyperalgesia encompassing primary hyperalgesia of the affected
joint and secondary hyperalgesia of distal, unaffected sites are a
common symptom in RA and in rodent models of arthritis.4 15
We measured primary hyperalgesia of the hindknee joint, and
secondary hyperalgesia in the hindpaw of WT and TRPC5 KO
mice following CFA-induced arthritis. At baseline, no difference
was observed between the groups (ﬁgure 2A–C). Over a period
of 14 days, WT and TRPC5 KO mice developed primary hyper-
algesia of the knee joint (ﬁgure 2A) and this was exacerbated in
TRPC5 KO compared with WT mice (p<0.05). Following
CFA-induced arthritis, bilateral thermal hyperalgesia was
observed in both groups with augmented ipsilateral hyperalgesia
in TRPC5 KO mice (ﬁgure 2B, p<0.05). Similarly, secondary
mechanical allodynia of the ipsilateral hindpaw (ﬁgure 2C) was
enhanced in TRPC5 KO compared with WT mice (p<0.05).
We investigated the mRNA expression of inﬂammatory media-
tors in the synovium 14 days following CFA-induced arthritis and
observed a signiﬁcant induction in the expression of the nuclear
transcription factor kappa B in the ipsilateral synovium of
TRPC5 KO mice (ﬁgure 2D). Similarly, we observed a poten-
tiated induction in the expression of inﬂammatory mediators
such as monocyte chemotactic protein 1 and tumour necrosis
factor α (TNFα) in TRPC5 KO mice compared with WT mice,
suggesting augmented synovitis. However, the expression of the
T cell marker, cluster of differentiation 3, was signiﬁcantly
increased in both TRPC5WTand KO mice highlighting increased
inﬁltration of lymphocytes following CFA-induced arthritis.
Deletion of TRPC5 enhances synovitis and local
inﬂammation
Synovitis, characterised by synovial inﬂammation, is a hallmark
of arthritic joint conditions and is predominantly driven by resi-
dent FLS, which contribute to the inﬂammation by recruiting
and activating immune cells.16 We investigated joint histopath-
ology 14 days following CFA-induced arthritis and observed sig-
niﬁcant synovitis in WT mice, as illustrated by thickening of the
synovium lining, cellularisation and inﬁltration (ﬁgure 3A).
Deletion of TRPC5 resulted in a signiﬁcantly increased synovitis
score compared with WT CFA (p<0.05). Assessment of the
leucocyte population of synovial lavage ﬂuid by cytospin pre-
parations illustrated an increase in mononuclear cell inﬁltrate in
the synovial ﬂuid of WT mice 14 days following CFA-induced
arthritis (ﬁgure 3B). By contrast, TRPC5 KO mice exhibited a
predominant inﬁltration of neutrophils (ﬁgure 3B) while circu-
lating leucocytes demonstrated no signiﬁcant difference com-
pared with WT mice (see online supplementary ﬁgure S2).
We investigated the mRNA expression of MMPs with an
established role in arthritic conditions,17 18 such as MMP-2,
MMP-3 and MMP-13. Results demonstrated a signiﬁcant induc-
tion in the expression of these enzymes in the ipsilateral syno-
vium of TRPC5 KO mice (ﬁgure 3C). Additionally, the
expression of the endogenous inhibitors of MMPs and tissue
inhibitors of metalloproteinases was investigated, which demon-
strated a signiﬁcant reduction in the expression of tissue inhibi-
tors of MMP (TIMP)-2 and TIMP-3 in the ipsilateral synovium
of TRPC5 KO mice (ﬁgure 3D; p<0.01 and <0.001, respect-
ively), while the expression of TIMP-4 was reduced in the ipsi-
lateral synovium of both WTand TRPC5 KO mice (p<0.001).
Chronic pharmacological antagonism of TRPC5 exacerbates
inﬂammation
To conﬁrm the ﬁndings obtained in genetically modiﬁed mice,
we used the TRPC4/5 antagonist, ML204.11 ML204 or vehicle
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was administered 1 h prior to induction of arthritis and daily
thereafter (see online supplementary ﬁgure S3A). Chronic treat-
ment with ML204 had no effect on body weight (see online
supplementary ﬁgure S3B), but signiﬁcantly augmented joint
inﬂammation, hyperalgesia and weightbearing asymmetry in
WT mice (ﬁgure 4A–C). We investigated the selectivity of
ML204 by performing parallel experiments in TRPC5 KO mice
and noted no differences between TRPC5 KO mice treated with
ML204 or vehicle (ﬁgure 4A–C). Cytokine concentrations
(interferon (IFN)-γ, TNFα and interleukin (IL)-10) in the ipsilat-
eral synovial ﬂuid of WT mice treated with ML204 were
increased compared with ipsilateral synovial ﬂuid of vehicle-
treated WT mice (ﬁgure 4D). IL-6, IL-1β and the chemokine,
keratinocyte chemoattractant, exhibited a similar trend (not sig-
niﬁcant). Moreover, TRPC5 KO mice treated with vehicle or
ML204 showed no difference in cytokine concentrations;
however, IFN-γ, TNFα and IL-10 concentrations were augmen-
ted in TRPC5 KO mice compared with vehicle-treated WT
mice. Circulating cytokines were also investigated (see online
supplementary ﬁgure S4), and no distinct differences were
observed in all groups.
TRPC5 regulates synovial vascularity and joint oedema
Enhanced synovial vascularity is an indicator of disease activity in
RA19 20 and has been determined in rodent models.21 22 We
investigated synovial blood ﬂow following CFA-induced arthritis
by laser speckle imaging. The results demonstrated that following
CFA-induced arthritis, the ipsilateral synovial membrane was sig-
niﬁcantly vascularised on day 7 compared with the contralateral
synovium. In contrast, synovial blood ﬂow on day 14 showed a
modest reduction in the ipsilateral synovium, although this did
not reach signiﬁcance (see online supplementary ﬁgure S5). At
day 14 following CFA-induced arthritis in WT and TRPC5 KO
mice, we observed no signiﬁcant change in blood ﬂow of the ipsi-
lateral synovium of TRPC5 WT mice compared with the contra-
lateral synovium. Conversely, blood ﬂow was signiﬁcantly
increased in the ipsilateral synovium of TRPC5 KO mice com-
pared with the contralateral (p<0.01) and with WT mice
(p<0.001) (ﬁgure 5A). Consistent with previous results, chronic
TRPC5 antagonism with ML204 closely mimicked the TRPC5
KO results, whereby ipsilateral synovial blood ﬂow was signiﬁ-
cantly increased compared with the contralateral synovium and
with vehicle-treated WT mice (ﬁgure 5B).
We assessed joint swelling by measuring thickness following
CFA-induced arthritis and observed a signiﬁcant increase by day
7 in both WT and TRPC5 KO mice; however, swelling was aug-
mented in TRPC5 KO mice on day 14 compared with WT mice
(ﬁgure 5C; p<0.05). Assessment of joint diameter compared
with baseline at days 7 and 14 illustrated a signiﬁcant amelior-
ation (day 14 vs day 7, p<0.01) in TRPC5 WT mice; this was
not observed in TRPC5 KO mice, where the mean change in
knee joint diameter was signiﬁcantly higher compared with WT
mice (ﬁgure 5E; p<0.05). TRPC5 WT mice treated with
ML204 did not show a signiﬁcant difference compared with
vehicle-treated WT mice (ﬁgure 5D); however, vehicle-treated
WT mice displayed resolution of joint swelling by day 14
(p<0.01), and this was absent in ML204-treated WT mice
(ﬁgure 5F).
Figure 1 Transient receptor potential canonical 5 (TRPC5) mRNA expression is regulated in the arthritic synovium; evidence that deletion
exacerbates complete Freund’s adjuvant (CFA)-induced arthritis. (A) Real-time PCR analysis of TRPC5 expression in the synovial membrane of
wild-type (WT) mice 14 days following saline or CFA, normalised to hypoxanthine-guanine phosphoribosyltransferase (HPRT), β-actin and PLA2; n=7.
(B) Representative double immunoﬂuorescence staining of CD55 (green) and TRPC5 (red) in normal and arthritic synovium, scale bars represent
50 mm. (C) Time-course analysis of weightbearing asymmetry following induction of arthritis in TRPC5 WT (n=9) and TRPC5 knockout (KO) (n=8)
mice. *p<0.05, **p<0.01, ***p<0.001 vs control; ###p<0.001 vs WT by two-tailed Student’s test (A) and two-way analysis of variance+Bonferroni
post hoc test (C); values are mean±SEM.
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Regulation of TRPC5 expression in human arthritis
We investigated the mRNA expression of TRPC5 in human
synovium under normal and inﬂammatory conditions encom-
passing RA and OA (see online supplementary table S1 for
patient details and inﬂammation scores). We detected TRPC5
expression in control synovium (ﬁgure 6A), and similar to
results observed in our ﬁndings in mice, TRPC5 expression
exhibited a trend towards a reduction in RA samples; however,
this was not signiﬁcant. In contrast, TRPC5 expression was sig-
niﬁcantly reduced in OA samples (p<0.05) compared with non-
arthritic controls. In contrast, the expression of the type 1 TNF
receptor and vascular adhesion molecule-1 were signiﬁcantly
increased in arthritic synovium compared with the control syno-
vium (p<0.05; ﬁgure 6B, C), paralleling increased inﬂammatory
responses in these samples, and the histological synovitis scores
(see online supplementary table S1).
DISCUSSION
In the present study, we investigated the in vivo contribution of
TRPC5 to the local inﬂammatory changes that occur in arthritis
using pharmacogenomic approaches. We show that genetic dele-
tion or blockade of TRPC5 in arthritic mice resulted in marked
exacerbation of hyperalgesia and, critically, increased localised
inﬂammation in the synovium characterised by increased cellular
inﬁltration, secretion of early response cytokines and enhanced
synovial vascularisation. This provides the ﬁrst in vivo evidence
to show that TRPC5 acts as a regulatory channel to protect the
joint against inﬂammatory insults.
Joint pain remains an unmet clinical need,1 and patients with
RA exhibit symmetry in both their clinical symptoms and pain.
Peripheral and central sensitisation, characterised by pain radiat-
ing to an unaffected site, is a common feature.4 15 23 We
designed experiments to investigate this by inducing unilateral
Figure 2 Nociceptive parameters assessment in complete Freund’s adjuvant (CFA)-induced arthritis in wild-type (WT) and transient receptor
potential canonical 5 (TRPC5) knockout (KO) mice. (A) Time-course analysis of primary hyperalgesia of the hindlimb in TRPC5 WT (n=9) and KO
(n=8) mice. (B) Secondary thermal hyperalgesia assessed before and weekly following CFA-induced arthritis in TRPC5 WT and KO mice. (C)
Secondary mechanical hyperalgesia in the hindpaw assessed before and weekly following CFA-induced arthritis in TRPC5 WT and KO mice. (D)
Real-time quantitative PCR analysis of the expression of inﬂammatory mediators: nuclear factor of kappa light polypeptide gene enhancer in B cells
(NF-κB), monocyte chemoattractant protein-1 (MCP-1), tumour necrosis factor α (TNFα), cluster of differentiation 3 (CD3) in the contralateral and
ipsilateral synovium of TRPC5 WT (n=8) and KO (n=7) mice, normalised to hypoxanthine-guanine phosphoribosyltransferase (HPRT), β-actin and
PLA2. *p<0.05, **p<0.01, ***p<0.001 vs control; #p<0.05, ##p<0.01 vs WT by two-way analysis of variance +Bonferroni post hoc test; values are
mean±SEM.
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arthritis, which resulted in primary hyperalgesia, in addition to
symmetrical secondary hyperalgesia. We conﬁrmed the develop-
ment of primary hyperalgesia through measurement of joint
withdrawal threshold to pressure application and weightbearing
asymmetry; both parameters were principally unilateral in
nature and signiﬁcantly exacerbated in TRPC5 KO mice.
We investigated central sensitisation1 by measuring nocicep-
tive responses in the hindpaw and show the development of
bilateral hyperalgesia following intra-articular injection of CFA
in the hindknee joint. While the contralateral secondary hyper-
algesia was not inﬂuenced by TRPC5 deletion/antagonism, sec-
ondary ipsilateral hyperalgesia was signiﬁcantly enhanced in
Figure 3 Genetic deletion of transient receptor potential canonical 5 (TRPC5) enhances synovitis and cellular inﬁltration following complete
Freund’s adjuvant (CFA)-induced arthritis. (A) Histological assessment of synovitis assessed by H&E staining; top panel shows the tibiofemoral
junction (×4) 14 days following saline or CFA injection, inset shows higher power magniﬁcation (×20) below. Each knee shown is a representative
for a group of mice (n=5–6); scale bars (×4) represents 200 mm, (×20) represents 50 mm; T, tibia; F, femur; S, synovium. (B) Cytospin preparations
of synovial lavage ﬂuid of wild-type (WT) and TRPC5 knockout (KO) mice illustrating cellular inﬁltration 14 days following CFA-induced arthritis and
leucocyte population analysis. (C) Real-time quantitative PCR analysis of the expression of matrix metalloproteinases (MMP-2, MMP-3, MMP-13) in
the ipsilateral synovium compared with the contralateral synovium in TRPC5 WT (n=8) and KO (n=7) mice. (D) Expression of tissue inhibitors of
MMP (TIMP-2, TIMP-3, TIMP-4) in the ipsilateral synovium compared with the contralateral synovium in TRPC5 WT (n=8) and KO (n=7) mice,
normalised to hypoxanthine-guanine phosphoribosyltransferase (HPRT), β-actin and PLA2..*p<0.05, **p<0.01, ***p<0.001 vs control; #p<0.05,
##p<0.01 vs WT by two-way analysis of variance+Bonferroni post hoc test; values are mean±SEM.
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TRPC5 KO and WT antagonist-treated mice. The role of TNFα
in inﬂammatory hyperalgesia is fundamental23–25; we detected
abundant expression of TNFα mRNA in the inﬂamed synovium
of both TRPC5 WT and KO mice, 14 days following
CFA-induced arthritis. However, the induction of TNFα was
substantially elevated in TRPC5 KO mice. Furthermore, assess-
ment of TNFα concentrations in synovial lavage ﬂuid was in
agreement with the mRNA studies, highlighting enhanced
synthesis and secretion of TNFα following deletion of TRPC5.
As a potent pro-algesic mediator, this increase in TNFα avail-
ability may facilitate the augmented hyperalgesia observed in
TRPC5 KO mice.
Synovitis, characterised by synovial hyperplasia and inﬂamma-
tion, is a hallmark of RA, with a prominent role for FLS.14
Here, we show positive TRPC5 expression in the mouse syno-
vium and co-localisation with CD55. CD55-positive staining
Figure 4 Chronic pharmacological blockade of transient receptor potential canonical 5 (TRPC5) exacerbates complete Freund’s adjuvant
(CFA)-induced arthritis in wild-type (WT) mice. (A) Time-course analysis of weightbearing asymmetry in vehicle (2% dimethyl sulfoxide (DMSO) in
saline, intraperitoneally)-treated WT and TRPC5 knockout (KO) mice (n=5), ML204-treated WT and TRPC5 KO mice (2 mg/kg, intraperitoneally, daily
n=6). (B) Secondary thermal hyperalgesia assessed before and weekly following CFA-induced arthritis in TRPC5 WT and KO mice treated with
vehicle or ML204. (C) Secondary mechanical hyperalgesia in the hindpaw assessed before and weekly following CFA-induced arthritis in TRPC5 WT
and KO mice treated with vehicle or ML204. (D) Cytokine concentrations in the synovial lavage ﬂuid 14 days following CFA-induced arthritis in
TRPC5 WT and KO mice treated with vehicle or ML204; interferon-γ (IFN-γ), tumour necrosis factor-α (TNFα), interleukin (IL)-6, IL-10 and IL-1β,
keratinocyte chemoattractant (KC). *p<0.05, **p<0.01, ***p<0.001 vs baseline (A–C) and versus control (E); #p<0.05, ##p<0.01, ###p<0.001 vs
WT vehicle by two-way analysis of variance+Bonferroni post hoc test; values are mean±SEM.
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was observed in the intimal lining layer, while TRPC5 was
found both in the intimal and subintimal lining. Co-localisation
of TRPC5 with CD55 was previously shown in human RA syno-
vium10; however, the transcriptional expression of TRPC5
under joint inﬂammation was previously unknown. Thus, we
investigated the mRNA expression of TRPC5 and demonstrated
a reduction in inﬂamed human arthritis samples. Interestingly,
downregulation of TRPC5 was pronounced in synovium from
Figure 5 Augmented synovial
vascularity and swelling in transient
receptor potential canonical 5 (TRPC5)
knockout (KO) and antagonist-treated
wild-type (WT) mice. (A) Top panel:
representative ﬂux/blood ﬂow image
obtained by full-ﬁeld laser perfusion
imaging of blood ﬂow in the synovial
membrane day 14 following complete
Freund’s adjuvant (CFA)-induced
arthritis in TRPC5 WT (n=7) and
TRPC5 KO (n=7) mice with graphical
representation of the results. (B)
Synovial blood ﬂow (top panel)
assessed on day 14 following
CFA-induced arthritis in vehicle (2%
dimethyl sulfoxide (DMSO) in saline,
intraperitoneally)-treated WT (n=5) and
ML204-treated mice (2 mg/kg,
intraperitoneally, daily n=6) on day 14
following CFA-induced arthritis with
graphical representation of the results.
(C) Time course of knee diameter
swelling following CFA-induced
arthritis in TRPC5 WT (n=10) and KO
(n=10) mice and (E) delta (Δ) change
in knee joint swelling. (D) Time course
of joint swelling following CFA-induced
arthritis in vehicle (2% DMSO in
saline, intraperitoneally)-treated WT
(n=5) and ML204-treated mice
(2 mg/kg, intraperitoneally, daily n=6)
following CFA-induced arthritis and (F)
delta (Δ) change in knee joint
diameter. *p<0.05, **p<0.01,
***p<0.001 vs control (A and B)
versus baseline (C and D); ##p<0.01
vs WT by two-way analysis of variance
+Bonferroni post hoc test; values are
mean±SEM.
Figure 6 Expression of transient receptor potential canonical 5 (TRPC5) in human synovium under normal and inﬂammatory arthritis conditions.
Real-time quantitative PCR analysis of the expression of (A) TRPC5, (B) tumour necrosis factor receptor 1 (TNF-R1) and (C) vascular cell adhesion
molecule (VCAM-1) in the synovium of postmortem (PM) control, rheumatoid arthritis (RA) and osteoarthritis (OA) normalised to β-actin, B2M, and
RPL13A. *p<0.05 vs control, as determined by Kruskal–Wallis test followed by Dunn’s post hoc comparison; values are mean±SEM.
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patients with OA, highlighting a potential role for TRPC5 in
OA. However, this remains to be investigated. Collectively, the
results were in agreement with our mouse model of
CFA-induced arthritis, revealing an association between TRPC5
expression and joint inﬂammation. Indeed, genetic deletion of
TRPC5 signiﬁcantly increased the synovitis score in mice, as
illustrated by signiﬁcantly increased cellularity of resident and
inﬁltrating cells.
Hyperpermeability, angiogenesis and vascular remodelling
contribute to the inﬂammatory response in arthritis.20 26 27
Altered synovial vascularisation is dependent on disease activ-
ity,26 28 where increased vascularisation reﬂects an increase in
sensory innervation and pain,29 30 while in chronic RA, the
synovium exhibits hypoperfusion.31 In line with this, we show
that in WT mice, synovial vascularisation was pronounced on
day 7, but unchanged compared with the contralateral synovium
by day 14. A matched assessment of synovial blood ﬂow in
TRPC5 WT and KO mice revealed a different proﬁle in the
latter group, where synovial blood ﬂow was signiﬁcantly
increased, suggesting increased angiogenesis and/or innervation.
RA as an inﬂammatory disease exhibits distinct stages (ie,
acute/early RA vs chronic/established RA) characterised by differ-
ent immunogenic signatures32 and symptoms.33 The leucocyte
population in synovial lavage ﬂuid following CFA-induced arth-
ritis was assessed to investigate leucocyte inﬁltration into the
synovium. We show that deletion of TRPC5 resulted in an unex-
pected, neutrophil-driven inﬂammation 14 days following
induction of arthritis. The contribution of neutrophils in
murine models of inﬂammatory arthritis is established,34 and in
CFA-induced arthritis, neutrophil inﬁltration peaks earlier at
18–24 h following induction and is then substantially reduced
by 14 days.35 In WT mice, we observed the typical mononuclear
cell-driven inﬂammation 14 days post CFA-induced arthritis,
which is similar to leucocyte populations found in patients with
established arthritis.36–38 Mononuclear cellular inﬁltrate in the
inﬂamed synovium did not differ between WT and TRPC5 KO
mice; additionally, circulating leucocytes did not differ between
WT and TRPC5 KO mice. Collectively, these results indicate
that the protective role of TRPC5 is localised to the synovium,
with neutrophils, in addition to mononuclear cells playing an
important role in sustaining the inﬂammatory response.
We corroborated these results by measuring cytokine concen-
trations in synovial lavage ﬂuid and in plasma samples and show
that TRPC5 deletion or antagonism increased the local secretion
of a number of critical pro-inﬂammatory cytokines (eg, TNFα,
IL-1β) with an established role in joint disease. A positive correl-
ation between disease activity and cytokine concentrations in
clinical and animal models of arthritis has been previously estab-
lished.39 40 These cytokines are central to the pathogenesis of
RA, leading a network of events including the recruitment and
activation of inﬂammatory cells and propagation of joint
destruction by inducing the secretion of MMPs.17 18 In FLS
cells, extracellular reduced thioredoxin was shown to directly
stimulate TRPC5 and to suppress the secretion of MMPs,10 and
in line with this, we observed an enhanced induction in the
expression of MMPs in the inﬂamed synovium of TRPC5 KO
mice, suggesting accelerated synthesis of these enzymes.
Interestingly, we noted a signiﬁcant increase in the immunoregu-
latory and anti-inﬂammatory cytokine, IL-10,41 42 in TRPC5
KO and antagonist-treated WT mice, suggesting that IL-10
secretion was elevated to regulate the heightened inﬂammatory
response.
In summary, our results provide evidence of a potential role
for TRPC5 as a negative regulator of inﬂammation; in
particular, the early response cytokine TNFα-neutrophil-innate
immunity axis. We provide evidence that TRPC5 is protective in
a murine model of arthritis, where genetic deletion/pharmaco-
logical blockade of TRPC5 sustained active joint inﬂammation,
augmented hyperalgesia and synovitis. Taken together, our
results suggest that activation of endogenous TRPC5 initiates a
protective network against inﬂammatory insults and may facili-
tate novel therapeutic strategies for RA.
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